8-CN是一种2-氨基噻吩衍生物,具有抗利什曼原虫活性,可用作利什曼病研究的工具。
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | 2-acetamido-4,5,6,7,8,9-hexahydrocycloocta[b]thiophene-3-carbonitrile | 543715-40-8 | C13H16N2OS | 248.349 |
—— | 2-(N-ethylcarbamothioylamino)-4,5,6,7,8,9-hexahydrocyclo-octa[b]thiophene-3-carbonitrile | 1374968-02-1 | C14H19N3S2 | 293.457 |
2-氨基-4,5,6,7,8,9-六氢辛基[b]噻吩-3-羧酰胺 | 2-amino-4,5,6,7,8,9-hexahydrocycloocta[b]thiophene-3-carboxamide | 40106-15-8 | C11H16N2OS | 224.327 |
—— | 2-Acetamido-4,5,6,7,8,9-hexahydrocycloocta[b]thiophene-3-carboxamide | 354998-02-0 | C13H18N2O2S | 266.364 |
—— | 2-(cyclopropanecarboxamido)-4,5,6,7,8,9-hexahydrocycloocta[b]thiophene-3-carboxamide | 352706-04-8 | C15H20N2O2S | 292.402 |
—— | 2-benzamido-4,5,6,7,8,9-hexahydrocycloocta[b]thiophene-3-carboxamide | 438541-97-0 | C18H20N2O2S | 328.435 |
—— | 2-(cyclopentanecarboxamido)-4,5,6,7,8,9-hexahydrocycloocta[b]thiophene-3-carboxamide | 445229-59-4 | C17H24N2O2S | 320.456 |
—— | 2-(4-methylbenzamido)-4,5,6,7,8,9-hexahydrocycloocta[b]thiophene-3-carboxamide | 321533-48-6 | C19H22N2O2S | 342.462 |
—— | 2-(cyclohexanecarboxamido)-4,5,6,7,8,9-hexahydrocycloocta[b]thiophene-3-carboxamide | 544692-54-8 | C18H26N2O2S | 334.483 |
—— | 2-(4-phenoxybenzamido)-4,5,6,7,8,9-hexahydrocycloocta[b]thiophene-3-carboxamide | 1585244-80-9 | C24H24N2O3S | 420.532 |
—— | 2-(1-naphthamido)-4,5,6,7,8,9-hexahydrocycloocta[b]thiophene-3-carboxamide | 354996-69-3 | C22H22N2O2S | 378.495 |
A novel series of 4-aminohexahydrocycloocta[4,5]thieno[2,3- d]pyrimidines, hexahydrocycloocta[4,5]thieno[2,3- d]-1,2,3-triazin-4-one and its N-3 substituted derivatives in addition to 3-aryl hexahydrocycloocta[4,5] thieno[2,3- e]-1,4-diazepin-5-ones were synthesised. Also, 2-(N-ethylcarbamothioylamino) hexahydrocycloocta[b] thiophene-3-carbonitrile and 19-imino tetradecahydrocycloocta[4’,5'] thieno[2’,3’:4,5]pyrimido[1,6- a] cycloocta[4,5]thieno [3,2- e]pyrimidine-9-thione were prepared. Almost all the synthesised compounds exhibited anti-tumour activity against human colon carcinoma (HCT 116) cell line in vitro. Five compounds (IC50: 15.92, 22.59, 25.85, 27.40 and 29.70 μM, respectively) exhibited 2.16 to 1.15 fold more potent antitumour activity than imatinib (IC50: 34.40 μM).